- Home
- ATNF vs VRAX Comparison
ATNF vs VRAX Comparison
Compare ATNF & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- VRAX
- Stock Information
- Founded
- ATNF 2016
- VRAX 2013
- Country
- ATNF United States
- VRAX United Kingdom
- Employees
- ATNF N/A
- VRAX N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ATNF Health Care
- VRAX Health Care
- Exchange
- ATNF Nasdaq
- VRAX Nasdaq
- Market Cap
- ATNF 5.0M
- VRAX 4.7M
- IPO Year
- ATNF N/A
- VRAX 2022
- Fundamental
- Price
- ATNF $0.88
- VRAX $0.85
- Analyst Decision
- ATNF
- VRAX Strong Buy
- Analyst Count
- ATNF 0
- VRAX 1
- Target Price
- ATNF N/A
- VRAX $3.00
- AVG Volume (30 Days)
- ATNF 40.3K
- VRAX 37.2K
- Earning Date
- ATNF 08-11-2025
- VRAX 02-05-2025
- Dividend Yield
- ATNF N/A
- VRAX N/A
- EPS Growth
- ATNF N/A
- VRAX N/A
- EPS
- ATNF N/A
- VRAX N/A
- Revenue
- ATNF N/A
- VRAX $6,331.00
- Revenue This Year
- ATNF N/A
- VRAX $5,169.18
- Revenue Next Year
- ATNF N/A
- VRAX $66.97
- P/E Ratio
- ATNF N/A
- VRAX N/A
- Revenue Growth
- ATNF N/A
- VRAX 7.03
- 52 Week Low
- ATNF $0.66
- VRAX $0.74
- 52 Week High
- ATNF $17.75
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- ATNF 42.06
- VRAX 45.02
- Support Level
- ATNF $0.95
- VRAX $0.74
- Resistance Level
- ATNF $0.96
- VRAX $0.88
- Average True Range (ATR)
- ATNF 0.07
- VRAX 0.07
- MACD
- ATNF 0.00
- VRAX 0.01
- Stochastic Oscillator
- ATNF 27.73
- VRAX 50.23
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.